What LYFE Capital does

LYFE Capital is a Singapore-headquartered, transpacific healthcare-focused private equity platform founded in 2015 by James Zhao, formerly Managing Partner of Vivo Capital's Asia practice. The firm invests across the healthcare value chain — pharmaceuticals, biotech, medical devices, diagnostics, CDMOs/CROs, vaccines, surgical robotics, medical aesthetics, and healthcare services — building control or significant minority positions in companies that can leverage Asia-based manufacturing, clinical, and cost advantages alongside U.S.-based innovation and commercial reach. LYFE operates through five global offices (Menlo Park, Singapore, Seoul, Shanghai, and Tokyo) with 11–50 employees and an investment team covering 14+ medical specialties; its senior bench combines investment veterans (ex-Vivo Capital, Credit Suisse, Heritas Capital, Avant Bio, Casdin Capital, Nomura Securities) with healthcare operators from Illumina, Bristol Myers Squibb, MSD, Amgen, Yangtze River Pharma, Fosun Group, and major investment banks (Goldman Sachs, Morgan Stanley).

The firm pursues an "Invest–Scale–Deliver" playbook: source healthcare companies essential to the global value chain, scale them through LYFE's transpacific network (revenue expansion, bolt-on M&A, leadership augmentation, operational improvement), and realize exits via IPOs and strategic M&A. Portfolio activity spans 16+ named companies, including ST Pharm (Korean oligonucleotide CDMO), Edge Medical (China surgical robotics, HK IPO 2025), Bora Pharmaceuticals (Taiwan CDMO), Profound Bio (Seattle ADC platform, acquired by Genmab), Fong's Engineering (Singapore MedTech CDMO, 2023 control buyout), Meitheal (U.S. specialty injectables), Recbio (Chinese vaccine developer), Jeisys Medical (Korean aesthetics), Noah Medical, Brightech, Neurona Therapeutics, MediLink, Sciwind, ChemLex, Kali Therapeutics, and the 2025 joint tender offer for Japan's Nihon Chouzai Group with Advantage Partners.

LYFE generates revenue through two streams: (1) recurring management fees on assets under management — most recently USD 935M closed in Fund IV (2022) as part of an overall USD 2B+ AUM platform backed by pension funds, endowments, fund of funds, family offices, and advisors — and (2) performance-based carried interest from realized exits (20+ IPOs and 10+ M&As to date). The firm markets and distributes its capabilities through direct, relationship-driven enterprise sales — a Director of Investor Relations and senior partners cultivate LPs, while investment professionals source deals directly from founders — supplemented by co-investment/club-deal partnerships (Advantage Partners) and content marketing via the corporate website and ESG disclosures. Singapore PDPA compliance, an ESG framework, and an internal governance structure (including an ESG coordinator role held by the Chief Legal Officer) support institutional LP requirements.

Name

LYFE Capital

Legal name

LYFE Capital Group

Website

https://lyfecapital.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

LYFE Capital is a Singapore-headquartered transpacific private equity firm that invests across pharmaceuticals, biotech, MedTech, and healthcare services in Asia and the U.S., managing over USD 2 billion in AUM through five global offices and serving global institutional LPs.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282), Finance Services (6199)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

akta.pro secondary industry

Managed Platforms & Wrap Programs for Private Clients (Model Portfolios, UMA/SMAs) (FSAAABAM)

Keywords

• Healthcare private equity
• Buyout investments
• Portfolio management
• Institutional fund management
• Transpacific healthcare investing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund Management Fees: Recurring management fees earned on assets under management from global institutional Limited Partners across multiple fund vintages (latest fund, Fund IV, closed in 2022 at USD 935 million).
2. Carried Interest / Performance Fees: Performance-based share of profits from successful exits (IPOs and M&A sales) generated across the portfolio; the firm reports 20+ IPOs and 10+ M&A exits to date.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

LYFE Capital is a transpacific healthcare-focused private equity investment platform that manages over USD 2 billion in assets across multiple fund vintages (latest Fund IV closed in 2022 at USD 935 million). The firm invests in healthcare supply chain assets, specialized product platforms, and next-generation R&D services across pharmaceuticals, medical devices, diagnostics, and healthcare services, then scales those companies using cross-border resources, top-tier talent, and operational support between Asia and the U.S. The platform is delivered through three intertwined service pillars — Invest, Scale, and Deliver — operated from 5 global offices covering 14+ medical specialties.

Product overview

LYFE Capital operates a single, unified transpacific healthcare investment platform managing over USD 2 billion in AUM (with USD 935 million closed in Fund IV alone in 2022), rather than a multi-module software product. The platform is organized around three intertwined service pillars — Invest (building positions in healthcare companies essential to the global value chain), Scale (scaling high-potential businesses through LYFE resources and bolt-on acquisitions between Asia and the U.S.), and Deliver (consistent returns to worldwide institutional investors) — applied across its 14+ medical specialty coverage areas through 5 global offices in Menlo Park, Seoul, Singapore, Shanghai, and Tokyo. Portfolio company investments named on the platform include ST Pharm, Edge Medical, Profound Bio, Bora Pharmaceuticals, Brightech, Noah Medical, Jeisys Medical, Fong's Engineering, NIHON CHOUZAI, ChemLex, MediLink, Sciwind, Recbio, and Meitheal, and the firm has delivered 20+ IPOs and 10+ M&As across global capital markets.

Differentiator

Problem solved

Functional benefit

Products and services

• LYFE Healthcare Investment Platform Transpacific healthcare investment platform that connects healthcare champions with global markets, supply chains, and strategic partners, led by investment veterans and operators that have gone through several market cycles. Operates through 5 global offices across Asia and the U.S. and manages over USD 2 billion in AUM.
• LYFE Fund IV LYFE Capital's latest healthcare-focused private equity fund, which closed in 2022 with USD 935 million in commitments from global institutional investors including pensions, endowments, fund of funds, family offices, and advisors.
• Invest Service (Healthcare Investing) Core capability of LYFE Capital to invest in healthcare companies essential to the global value chain, building meaningful positions in high-growth potential leaders integral to the global healthcare ecosystem across pharma, medtech, diagnostics, and healthcare services.
• Scale Service (Portfolio Value Creation) Capability of LYFE Capital to scale high-potential businesses to market leaders through LYFE resources and expertise, driving returns organically through geographic revenue expansion and bolt-on acquisitions between Asia and the U.S.
• Deliver Service (LP Return Delivery) LYFE Capital's service of delivering consistent returns to worldwide institutional investors while leveraging Asia's cost benefits combined with U.S. innovation to create healthcare champions.

Quantifiable outcome

• USD 2.0 billion+ in assets under management
• +7 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Advantage PartnersflagshipStrategic or Co-development Partner · 31 July 2025Joint acquisition of NIHON CHOUZAI Co., Ltd. (TSE Prime: 3341) through a tender offer via special purpose company AP86 Co., Ltd., jointly owned by funds serviced by Advantage Partners and LYFE Capital's affiliated funds. Marked LYFE Capital's first investment in Japan and signals a long-term co-investment platform combining AP's deep Japanese management improvement know-how with LYFE's global healthcare expertise.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Vivo Capital: US- and Asia-headquartered healthcare-focused private equity firm; the most direct peer because LYFE's founder James Zhao built Vivo's Asia practice before founding LYFE, and both firms invest across healthcare stages and geographies with comparable fund sizes.
• OrbiMed: Global healthcare-dedicated investment platform across private equity, venture, and royalty financing; directly comparable in healthcare-only mandate, multi-stage approach, and global reach serving similar pharma/MedTech/diagnostics LPs and portfolio companies.
• C-Bridge Capital: China- and US-headquartered healthcare-focused growth and buyout investor; a direct competitor for cross-border Asia-US healthcare deals of the size LYFE targets, with overlapping focus on pharma, MedTech, and CDMO assets.
• Eight Roads Ventures: Global healthcare and technology investment arm of Fidelity with deep Asia footprint; comparable healthcare focus and Asia-US deal flow, though generally earlier-stage than LYFE's buyout orientation.
• Kohlberg & Company: US middle-market private equity firm with a long-standing healthcare specialization across pharma services, MedTech, and diagnostics; comparable in healthcare-only mid-market buyout focus and operating-partner value creation model.

Broad incumbents

• Hillhouse Capital: Asia-anchored multi-strategy investment platform with a large, active healthcare franchise spanning biopharma, MedTech, and services; broader than LYFE but overlaps heavily on Asia healthcare investing and LP base.
• Blackstone Life Sciences: Life-sciences arm of Blackstone investing across pharma, MedTech, and biotech at scale; broader incumbent competing for the same institutional LPs and large healthcare buyouts that LYFE targets.
• EQT Life Sciences: Global healthcare-dedicated franchise of EQT spanning venture, growth, and buyout across Europe, US, and Asia; overlaps with LYFE in life sciences and MedTech buyouts at comparable check sizes.

Regional players

• Legend Capital: China-based PE platform with a substantial healthcare practice covering pharma, MedTech, and diagnostics; comparable in cross-border Asia healthcare deal-making though primarily China-domiciled.
• Lake Bleu Capital: Hong Kong-based long-only and private investment manager focused on Asia healthcare equities and growth deals; comparable in Asia healthcare specialization though more public-market-tilted than LYFE's private equity model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lyfe-capital

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments81 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LYFE Capital